In 2015, one of us published a peer-reviewed study, together with colleagues at the University of California, San Francisco, replicating prior research from the US Food and Drug Administration (FDA) detecting a designer stimulant, β-methylphenylethylamine, in sports, weight loss, and “cognitive function” supplements sold in the United States.1,2 The confirmatory study prompted the FDA to take enforcement action against companies selling the stimulant as a dietary ingredient.3
Bagley N, Carroll AE, Cohen PA. Scientific Trials—In the Laboratories, Not the Courts. JAMA Intern Med. 2018;178(1):7–8. doi:10.1001/jamainternmed.2017.5730
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: